SG11201909932YA - Pharmaceutical agents, compositions, and methods relating thereto - Google Patents
Pharmaceutical agents, compositions, and methods relating theretoInfo
- Publication number
- SG11201909932YA SG11201909932YA SG11201909932YA SG11201909932YA SG 11201909932Y A SG11201909932Y A SG 11201909932YA SG 11201909932Y A SG11201909932Y A SG 11201909932YA SG 11201909932Y A SG11201909932Y A SG 11201909932YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- nicholasville
- catnip
- hill road
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Abstract
adenosine} miM1158 12',V- Dideoxyodenol4m8 -4,360 (V- Deoxyadeosine) -0-#81 (3Q22,536) -11-#82 (Adenine) -0-*63 (NAD) (SAM) -•-#68 (Sulfur amain of 043) 22 2.2 1.3 1.0 1.4 0.8 0..4 0.0 443 -1,4CDE --C -0-40 -0-8E -4-489 -0-370 2 * NIP Compound COMantreion (FM) \"4\" why 4 Compound concentration (pfd) .0 ID \"t• Fig. 1 2.0 1.8 4.8 0.3 0.4 0.2 0.0 c M © cr (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 November 2018 (22.11.2018) WIPO I PCT Hu omit VIII °nolo III 0111 VIII Oil u moilowo oimIE (10) International Publication Number WO 2018/212980 Al (51) International Patent Classification: A61K 31/7076 (2006.01) (21) International Application Number: PCT/US2018/030371 (22) International Filing Date: 01 May 2018 (01.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/508,730 19 May 2017 (19.05.2017) US (71) Applicant: ALLTECH, INC. [US/US]; 3031 Catnip Hill Road, Nicholasville, KY 40356 (US). (72) Inventors: LAN, Zi-Jian; c/o Alltech, Inc., 3031 Catnip Hill Road, Nicholasville, KY 40356 (US). POWER, Ro- nan; c/o Alltech, Inc., 3031 Catnip Hill Road, Nicholasville, KY 40356 (US). YIANNIKOURIS, Alexandros; c/o All- tech, Inc., 3031 Catnip Hill Road, Nicholasville, KY 40356 (US). YERRAMREDDY, Thirupathi, Reddy; c/o All- tech, Inc., 3031 Catnip Hill Road, Nicholasville, KY 40356 (US). (74) Agent: JARRELL, Brenda, Herschbach et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO 1-1 (57) : The present disclosure provides compounds of formulas (1)-(3), and compositions and methods of use thereof. The present disclosure also provides methods of preparing a provided compound and composition, and methods of characterizing a provided C compound and composition. [Continued on next page] WO 2018/212980 Al MIDEDIMOMMIDIREIEHIHOHOHHEIHMEMOIMIE Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508730P | 2017-05-19 | 2017-05-19 | |
| PCT/US2018/030371 WO2018212980A1 (en) | 2017-05-19 | 2018-05-01 | Pharmaceutical agents, compositions, and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909932YA true SG11201909932YA (en) | 2019-11-28 |
Family
ID=64274560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909932Y SG11201909932YA (en) | 2017-05-19 | 2018-05-01 | Pharmaceutical agents, compositions, and methods relating thereto |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11014954B2 (en) |
| EP (1) | EP3624809A4 (en) |
| JP (1) | JP7224303B2 (en) |
| CN (1) | CN110545822A (en) |
| AU (1) | AU2018269403A1 (en) |
| BR (1) | BR112019022918A2 (en) |
| CA (1) | CA3061893A1 (en) |
| RU (1) | RU2765286C2 (en) |
| SA (1) | SA519410561B1 (en) |
| SG (1) | SG11201909932YA (en) |
| WO (1) | WO2018212980A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2765286C2 (en) | 2017-05-19 | 2022-01-28 | Оллтек, Инк. | Pharmaceutical agents, compositions, and methods related thereto |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002077002A2 (en) * | 2001-03-22 | 2002-10-03 | Research Foundation Of The City University Of New York | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids |
| US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| EP1652519A1 (en) | 2004-10-28 | 2006-05-03 | Tamie Nasu | Seleniferous composition for producing antioxidase in vivo |
| US20060198906A1 (en) | 2005-03-07 | 2006-09-07 | Sami Labs Limited | Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease |
| US20070077238A1 (en) | 2005-10-04 | 2007-04-05 | Teo Alex Y | Production of organic and inorganic selenium compounds by lactic acid bacteria |
| US7488720B2 (en) | 2005-10-13 | 2009-02-10 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| WO2009032057A2 (en) | 2007-08-29 | 2009-03-12 | Adam Lubin | Method for the selective therapy of disease |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| CA2903845C (en) | 2013-03-15 | 2022-08-23 | Alltech, Inc. | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction |
| JP6313479B2 (en) | 2014-03-14 | 2018-04-18 | オールテック，インク． | Composition of organic selenium compound and method of use thereof |
| US20160090397A1 (en) | 2014-09-30 | 2016-03-31 | Northeastern University | Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities |
| WO2017048252A1 (en) * | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| RU2765286C2 (en) | 2017-05-19 | 2022-01-28 | Оллтек, Инк. | Pharmaceutical agents, compositions, and methods related thereto |
-
2018
- 2018-05-01 RU RU2019134865A patent/RU2765286C2/en active
- 2018-05-01 EP EP18801931.9A patent/EP3624809A4/en active Pending
- 2018-05-01 SG SG11201909932Y patent/SG11201909932YA/en unknown
- 2018-05-01 US US16/490,836 patent/US11014954B2/en active Active
- 2018-05-01 CN CN201880027339.7A patent/CN110545822A/en active Pending
- 2018-05-01 WO PCT/US2018/030371 patent/WO2018212980A1/en active Application Filing
- 2018-05-01 AU AU2018269403A patent/AU2018269403A1/en active Pending
- 2018-05-01 BR BR112019022918-3A patent/BR112019022918A2/en unknown
- 2018-05-01 JP JP2019563067A patent/JP7224303B2/en active Active
- 2018-05-01 CA CA3061893A patent/CA3061893A1/en active Pending
-
2019
- 2019-11-14 SA SA519410561A patent/SA519410561B1/en unknown
-
2021
- 2021-04-23 US US17/238,354 patent/US11613552B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210238216A1 (en) | 2021-08-05 |
| RU2019134865A3 (en) | 2021-06-30 |
| WO2018212980A1 (en) | 2018-11-22 |
| US11613552B2 (en) | 2023-03-28 |
| CN110545822A (en) | 2019-12-06 |
| US20200123191A1 (en) | 2020-04-23 |
| EP3624809A1 (en) | 2020-03-25 |
| AU2018269403A1 (en) | 2019-11-14 |
| RU2765286C2 (en) | 2022-01-28 |
| JP7224303B2 (en) | 2023-02-17 |
| JP2020520904A (en) | 2020-07-16 |
| SA519410561B1 (en) | 2024-03-06 |
| RU2019134865A (en) | 2021-06-21 |
| US11014954B2 (en) | 2021-05-25 |
| EP3624809A4 (en) | 2021-03-03 |
| CA3061893A1 (en) | 2018-11-22 |
| BR112019022918A2 (en) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201809669RA (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
| SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |